文献
J-GLOBAL ID:202202271688767438
整理番号:22A1023605
SARS-CoV-2変異体に対する強力で保護的なヒト中和抗体【JST・京大機械翻訳】
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
著者 (26件):
Shan Sisi
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Mok Chee Keng
(2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Mok Chee Keng
(3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Zhang Shuyuan
(4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China)
,
Lan Jun
(4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China)
,
Li Jizhou
(5School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China)
,
Yang Ziqing
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Wang Ruoke
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Cheng Lin
(6Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China)
,
Fang Mengqi
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Aw Zhen Qin
(2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Aw Zhen Qin
(3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Aw Zhen Qin
(7Infectious Disease Translation Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Yu Jinfang
(4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China)
,
Zhang Qi
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Shi Xuanling
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Zhang Tong
(8Beijing Youan Hospital, Capital Medical University, Beijing, China)
,
Zhang Zheng
(6Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China)
,
Wang Jianbin
(5School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China)
,
Wang Xinquan
(4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China)
,
Chu Justin Jang Hann
(2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Chu Justin Jang Hann
(3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Chu Justin Jang Hann
(7Infectious Disease Translation Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore)
,
Zhang Linqi
(1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China)
,
Zhang Linqi
(9Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China)
,
Zhang Linqi
(10Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, China)
資料名:
Frontiers in Immunology (Web)
(Frontiers in Immunology (Web))
巻:
12
ページ:
766821
発行年:
2021年
JST資料番号:
U7074A
ISSN:
1664-3224
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
スイス (CHE)
言語:
英語 (EN)